Peter A. Fasching

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology · 2012 · 2.7K citations

Medicine, Oncology, Breast Oncology +15

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.6K citations · Full text

Medicine, Oncology, Pharmacology +17

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2.1K citations

Medicine, Immunology, Oncology +14

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou, Sara Lindström, Joe Dennis et al. · Nature · 2017 · 1.6K citations · Full text

Medicine, Bioinformatics, Oncology +12